DelveInsight reports that over five key companies are actively engaged in developing more than five treatment therapies for Catheter-related bloodstream infections (CRBSI).
Catheter-related bloodstream infection Overview:
Catheter-related bloodstream infection (CRBSI) occurs when bacteria enter the bloodstream through an intravenous catheter. It is one of the most frequent, serious, and costly complications associated with central venous catheter (CVC) use and stands as the leading cause of hospital-acquired bloodstream infections. Intravascular catheters play a vital role in modern healthcare—especially for critically ill patients—by enabling the delivery of fluids, medications, blood products, nutritional support, and hemodynamic monitoring.
However, central venous catheters present the highest risk for device-associated infections compared to other medical devices. They are a major contributor to hospital-acquired bacteremia and septicemia, leading to increased patient morbidity and mortality. Most CRBSI cases are linked to CVC use, with studies showing that the risk of CRBSI is up to 64 times greater with CVCs than with peripheral venous catheters.
Request for a detailed insights report on CRBSI pipeline insights
“CRBSI Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the CRBSI Therapeutics Market.
Key Takeaways from the CRBSI Pipeline Report
-
DelveInsight’s CRBSI pipeline report highlights a dynamic landscape, with over five active companies engaged in developing more than five therapies targeting Catheter-related bloodstream infections (CRBSI). Key players, including Leonard-Meron Biosciences, Inc., are advancing novel treatment options aimed at enhancing CRBSI management. Among the notable therapies in the pipeline is Mino-Lok, which is currently in various stages of development.
-
A significant milestone was reached on November 15, 2023, when the U.S. FDA approved DefenCath®—the first and only FDA-approved antimicrobial catheter lock solution in the U.S.—for reducing the risk of CRBSIs in adult patients with kidney failure undergoing chronic hemodialysis via a central venous catheter.
CRBSI Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the CRBSI Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRBSI treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CRBSI market.
Download our free sample page report on CRBSI pipeline insights
CRBSI Emerging Drugs
-
Mino-Lok: Leonard-Meron Biosciences, Inc.
CRBSI Companies
Over five leading companies are currently working on developing therapies for Catheter-related Bloodstream Infection (CRBSI). Notably, Leonard-Meron Biosciences, Inc., along with several others, has drug candidates that have progressed to the most advanced stage of development—Phase III clinical trials.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
CRBSI pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
CRBSI Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging CRBSI Therapies and Key Companies: CRBSI Clinical Trials and advancements
CRBSI Pipeline Therapeutic Assessment
• CRBSI Assessment by Product Type
• CRBSI By Stage
• CRBSI Assessment by Route of Administration
• CRBSI Assessment by Molecule Type
Download CRBSI Sample report to know in detail about the CRBSI treatment market @ CRBSI Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. CRBSI Current Treatment Patterns
4. CRBSI – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. CRBSI Late-Stage Products (Phase-III)
7. CRBSI Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CRBSI Discontinued Products
13. CRBSI Product Profiles
14. CRBSI Key Companies
15. CRBSI Key Products
16. Dormant and Discontinued Products
17. CRBSI Unmet Needs
18. CRBSI Future Perspectives
19. CRBSI Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the CRBSI Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/